Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (7): 13-20.doi: 10.6040/j.issn.1671-7554.0.2019.208

Previous Articles     Next Articles

Current situation and prospect of immunotherapy for lymphoma

WU Depei1,2, CHEN Xiaochen1,2   

  1. 1.Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu, China;
    2.State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, Jiangsu, China
  • Published:2022-09-27

PDF (PC)

546

Abstract: Lymphoma is one of the most common hematological malignancies which has many subtypes and high heterogeneity. Traditional treatments include chemotherapy, radiotherapy and surgery. Patients with relapsed, refractory or advanced stage lymphoma still have dismal prognosis. In recent years, the development of immunotherapies for lymphoma has brought patients new hope. This paper reviews the current and novel immunotherapies for lymphoma, including monoclonal antibody therapy, immune checkpoint blockers, and chimeric antigen receptor T cells therapies.

Key words: Lymphoma, Immunotherapy, Monoclonal antibody therapy, Immune checkpoint, Chimeric antigen receptor T cell therapy

CLC Number: 

  • R733.4
[1] Minard CV, Brugieres L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead [J]. J Clin Oncol, 2015, 33(27): 2963-2974.
[2] Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma [J]. J Clin Oncol, 2014, 32(9): 912-918.
[3] Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101(obinutuzumab)compared with rituximab and ofatumumab in vitro and in xenograft models [J]. Mol Cancer Ther, 2013, 12(10): 2031-2042.
[4] Barth MJ, Chu Y, Hanley PJ, et al. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma [J]. Br J Haematol, 2016, 173(4): 597-616.
[5] Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab(GA101)monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study [J]. J Clin Oncol, 2013, 31(23): 2912-2919.
[6] Barth MJ, Hochberg J, Harrison L, et al. Phase 2 trial of obinutuzumab, a humanized glycoengineered monoclonal CD20 antibody, in combination with ifosfamide, carboplatin and etoposide for relapsed/refractory mature B-cell non-Hodgkin lymphoma [J]. Br J Haematol, 2018,182(Suppl 1): 48.
[7] Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin(SGN-35)for relapsed CD30-positive lymphomas [J]. N Engl J Med, 2010, 363(19): 1812-1821.
[8] Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression(AETHERA): a randomised, doubleblind, placebo-controlled, phase 3 trial [J]. Lancet, 2015, 385(9980): 1853-1862.
[9] Locatelli F, Mauz KC, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkins lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study [J]. Lancet Haematol, 2018, 5(10): 450-461.
[10] Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkins lymphoma AHOD1221): a Childrens Oncology Group, multicentre single-arm, phase 1-2 trial [J]. Lancet Oncol, 2018, 19(9): 1229-1238.
[11] Metzger ML, Flerlage JE, Krasin M, et al. Safety and early response to the first 2 cycles of Brentuximab vedotin substituting vincristine in the OEPA/COPDAC regimen for high risk pediatric Hodgkin lymphoma(HL)[J]. Hema Sphere, 2018, 2(7): 36.
[12] Kantarjian H, Jabbour E. Incorporating immunotherapy into the treatment strategies of B-cell adult acute lymphoblastic leukemia: the role of Blinatumomab and Inotuzumab Ozogamicin [J]. Am Soc Clin Oncol Educ Book, 2018, 38: 574-578. doi: 10.1200/EDBK_199505.
[13] Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective [J]. Pharmacol Ther, 2012, 136(3): 334-342.
[14] Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies [J]. Blood, 2018, 131(1): 30-38.
[15] Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager(BiTE)Antibody construct blinatumomab for the treatment of patients with Relapsed/Refractory non-Hodgkin lymphoma: final results from a phase I study [J]. J Clin Oncol, 2016, 34(10): 1104-1111.
[16] Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager(BiTE)antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma [J]. Blood, 2016, 127(11): 1410-1416.
[17] Awashti A, Edani D, Azmy C, et al. Blinatumomab significantly enhanced cytotoxicity and T-cell cytokine secretion against Burkitt lymphoma(BL)and primary mediastinal B-cell lymphoma(PMBL)[J]. Br J Haematol, 2016, 182(8): 67-75.
[18] Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies [J]. Blood, 2018, 131(1): 30-38.
[19] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[20] Ilcus C, Bagacean C, Tempescul A, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies [J]. Onco Targets Ther, 2017, 10(6): 2349-2363.
[21] Dada R. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review [J]. Ann Hematol, 2018, 97(4): 555-561.
[22] Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma [J]. N Engl J Med, 2015, 372(4): 311-319.
[23] Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkins lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial [J]. Lancet Oncol, 2016, 17(9): 1283-1294.
[24] Kasamon YL, De Claro RA, Wang YP, et al. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma [J]. Oncologist, 2017, 22(2): 585-591.
[25] Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory Bcell non-Hodgkin lymphoma [J]. Clin Cancer Res, 2009, 15(20): 6446-6453.
[26] Zinzani P, Ribrag V, Moskowitz CH, et al. Phase 1B study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-Cell lymphoma(rrPMBCL): updated results from the keynote-013 trial [J]. Hematol Oncol, 2017, 35(2): 189-190.
[27] Zinzani P, Thieblemont C, Melnichenko V, et al. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-Cell Lymphoma(rrPMBCL): updated analysis of the keynote-170 phase 2 trial [J]. Hematol Oncol, 2017, 35(S2): 62-63.
[28] Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study [J]. J Clin Oncol, 2016, 34(23): 2698-2704.
[29] Ansell S, Gutierrez ME, Shipp MA, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies(CheckMate 039)[J]. Blood, 2016, 128(2): 183.
[30] Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study [J]. J Clin Oncol, 2017, 35(12): 7519.
[31] Younes A, Burke JM, Diefenbach CS, et al. Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: an interim analysis [J]. Hematol Oncol, 2017, 35.
[32] Savoldo B, Ramos CA, Liu EL, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients [J]. J Clin Invest, 2011, 121(5): 1822-1826.
[33] Chen LP, Flies DB. Molecular mechanisms of T cell costimulation and co-inhibition [J]. Nat Rev Immunol, 2013, 13(4): 227-242.
[34] Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors [J]. Nat Med, 2015, 21(6): 581-590.
[35] Kawalekar OU, OConnor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells [J]. Immunity, 2016, 44(2): 380-390.
[36] Zhao ZG, Condomines M, Van DS, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells [J]. Cancer Cell, 2015, 28(4): 415-428.
[37] Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-Cell lymphoma [J]. Blood, 2017, 130(2): 577.
[38] Locke f, Neelapu S, Bartlett N, et al. Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel(axicel; KTE-C19)in patients with refractory aggressive non-Hodgkin lymphoma(NHL)[J]. AACR Annual Meeting, 2017, 77. doi:10.1158/1538-7445.
[1] XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35.
[2] TIAN Lijun, SANG Yujie, SUN Yujing, HAN Bing, QIN Chengyong, QI Jianni. The predictive value of systemic immune-inflammation index for immune checkpoint inhibitor treatment-related adverse reactions in patients with primary liver cancer [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 48-53.
[3] WU Siyu, SHEN Yelong, WANG Ximing. Radiomics predicts Ki-67 labeling index in primary central nervous system lymphomas [J]. Journal of Shandong University (Health Sciences), 2024, 62(11): 67-72.
[4] SONG Zhaolu, DONG Zhengxuan, PENG Chuanzhen, HUANG Caina, HU Keqing, HUANG Yongsheng, YAN Lei. Screening of prognosis-related RNA editing sites in clear cell renal cell carcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(9): 69-78.
[5] XIE Xiaoli, QIU Yu, WANG Lijuan. IFN-γ promots the proliferation of NHL by up-regulating PD-L1 via PI3K/Akt/mTOR pathway [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 11-19.
[6] HU Liyong, ZHONG Hao, FANG Juanjuan, GUO Wei, ZHANG Yulu, FAN Yidong. Prognostic value of CCR gene in clear cell renal cell carcinoma based on database [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 49-55.
[7] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[8] Huijiang GAO,Yucheng WEI. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[9] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[10] DENG Xiaohui, GUO Ling. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37.
[11] PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.
[12] Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73.
[13] WANG Jian, LI Jian, WANG Yong, ZHU Yaofeng. Baicalein induces apoptosis of bladder cancer cells via inhibition of the PI3K/AKT/mTOR pathway [J]. Journal of Shandong University (Health Sciences), 2019, 57(9): 74-82.
[14] HUANG Xiaojun. Advances of cellular immunotherapy for hematologic malignancies [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 1-5.
[15] ZHOU Daobin, ZHANG Yan. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis and treatment [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 31-39.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd